Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the three months and year ended March 31, 2013.
Quarter ended March 31, 2013 Highlights - compared to March 31, 2012
•Net sales of $165.1 million, increased $20.0 million, or 13.8%, however, volumes have slightly declined
•Gross profit, as a percentage of net sales was 72.4%, compared to 68.3%
Help employers find you! Check out all the jobs and post your resume.
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the three months and year ended March 31, 2013.
Quarter ended March 31, 2013 Highlights - compared to March 31, 2012
•Net sales of $165.1 million, increased $20.0 million, or 13.8%, however, volumes have slightly declined
•Gross profit, as a percentage of net sales was 72.4%, compared to 68.3%
Help employers find you! Check out all the jobs and post your resume.
